Clinical efficacy of new antifungal agents

被引：43

作者：

Kauffman, Carol A. ^{[1
]}

机构：

[1] Univ Michigan, Div Infect Dis, Dept Internal Med, Sch Med,Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA

来源：

CURRENT OPINION IN MICROBIOLOGY | 2006年 / 9卷 / 05期

关键词：

D O I：

10.1016/j.mib.2006.08.001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Several new options are now available for treating serious fungal infections. All three echinocandin agents currently available have been shown in randomized, blinded clinical trials to be efficacious in treating candidemia and invasive candidiasis. By contrast, the demonstrated efficacy of the echinocandins for the treatment of invasive aspergillosis has been based on historically controlled salvage treatment trials in patients failing or intolerant of other therapies. The new triazole agents, voriconazole and posaconazole, have a broad spectrum of antifungal activity. Voriconazole has become the agent of choice for invasive aspergillosis. On the basis of compassionate treatment data, posaconazole appears to be effective for treatment of zygomycosis. These agents have also been shown to be effective in the treatment of non-Aspergillus mould infections, several of the endemic mycoses and serious Candida infections.

引用

页码：483 / 488

页数：6

共 47 条

[1] Refractory coccidioidomycosis treated with posaconazole [J].

Anstead, GM ;

Corcoran, G ;

Lewis, J ;

Berg, D ;

Graybill, JR .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (12) :1770-1776

[2] Successful treatment of cerebral blastomycosis with voriconazole [J].

Bakleh, M ;

Aksamit, AJ ;

Tleyjeh, IM ;

Marshall, WF .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :E69-E71

[3] Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections [J].

Benjamin, DK ;

Driscoll, T ;

Seibel, NL ;

Gonzalez, CE ;

Roden, MM ;

Kilaru, R ;

Clark, K ;

Dowell, JA ;

Schranz, J ;

Walsh, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :632-638

[4] Micafungin: A new echinocandin [J].

Chandrasekar, PH ;

Sobel, JD .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) :1171-1178

[5]

Clark B, 2005, J Infect, V51, pe177, DOI 10.1016/j.jinf.2005.01.001

[6]

CORNELY O, 2005, 45 INT C ANT AG CHEM

[7] Successful treatment of coccidioidal meningitis with voriconazole [J].

Cortez, KJ ;

Walsh, TJ ;

Bennett, JE .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :1619-1622

[8] Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [J].

Denning, David W. ;

Marr, Kieren A. ;

Lau, Wendi M. ;

Facklam, David P. ;

Ratanatharathorn, Voravit ;

Becker, Cornelia ;

Ullmann, Andrew J. ;

Seibel, Nita L. ;

Flynn, Patricia M. ;

van Burik, Jo-Anne H. ;

Buell, Donald N. ;

Patterson, Thomas F. .

JOURNAL OF INFECTION, 2006, 53 (05) :337-349

[9] Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center [J].

Freifeld, AG ;

Iwen, PC ;

Lesiak, BL ;

Gilroy, RK ;

Stevens, RB ;

Kalil, AC .

TRANSPLANT INFECTIOUS DISEASE, 2005, 7 (3-4) :109-115

[10] Posaconazole as salvage therapy for zygomycosis [J].

Greenberg, RN ;

Mullane, K ;

van Burik, JAH ;

Raad, I ;

Abzug, MJ ;

Anstead, G ;

Herbrecht, R ;

Langston, A ;

Marr, KA ;

Schiller, G ;

Schuster, M ;

Wingard, JR ;

Gonzalez, CE ;

Revankar, SG ;

Corcoran, G ;

Kryscio, RJ ;

Hare, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :126-133

← 1 2 3 4 5 →